Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125029052 | 12502905 | 2 | F | 20160607 | 20160719 | 20160628 | 20160726 | EXP | NL-LRB-220981 | NL-009507513-1606NLD011256 | MERCK | 76.60 | YR | M | Y | 0.00000 | 20160726 | MD | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125029052 | 12502905 | 1 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, QD, (1 TIME A DAY 1 UNIT(S)) | 19766 | 40 | MG | TABLET | QD | ||||||
| 125029052 | 12502905 | 2 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 200 MG, BID (2 TIMES A DAY 1 UNIT(S)) | 7600 | MG | Y | 0 | 200 | MG | TABLET | BID | |||
| 125029052 | 12502905 | 3 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 80 MG, QD (1 TIME A DAY 1) | U | 0 | 80 | MG | DISPERSIBLE TABLET | QD | |||||
| 125029052 | 12502905 | 4 | C | MACROGOL HEXAL | ETHYLENE GLYCOL | 1 | Oral | 1 DF, QD (1 TIME A DAY 1) | U | 0 | 1 | DF | POWDER FOR ORAL SOLUTION | QD | |||||
| 125029052 | 12502905 | 5 | C | BECLOMETHASONE DIPROPIONATE | BECLOMETHASONE DIPROPIONATE | 1 | Respiratory (inhalation) | 2 DF, BID (2 TIMES A DAY 2 UNIT(S)) | U | 0 | 2 | DF | NASAL SPRAY, SOLUTION | BID | |||||
| 125029052 | 12502905 | 6 | C | NADROPARIN CALCIUM | NADROPARIN CALCIUM | 1 | Subcutaneous | 0.3 ML (1 TIME A DAY 1 UNIT AFTER DISCHARGED FROM THE HOSPITAL) | U | 0 | .3 | ML | SOLUTION FOR INJECTION | QD | |||||
| 125029052 | 12502905 | 7 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 12.5 MG, QD (1 TIME A DAY 1 UNIT) | U | 0 | 12.5 | MG | TABLET | QD | |||||
| 125029052 | 12502905 | 8 | C | TAMSULOSIN HYDROCHLORIDE. | TAMSULOSIN HYDROCHLORIDE | 1 | Oral | 0.4 MG, QD (1 TIME A DAY 1 UNIT) | U | 0 | .4 | MG | CAPSULE | QD | |||||
| 125029052 | 12502905 | 9 | C | ALBUTEROL SULFATE. | ALBUTEROL SULFATE | 1 | Respiratory (inhalation) | 100 MICROGRAM, IF NEEDED 4-6 TIMES A DAY 1 DOSE | U | 0 | 100 | UG | INHALATION VAPOUR, SOLUTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125029052 | 12502905 | 1 | Hypercholesterolaemia |
| 125029052 | 12502905 | 2 | Bronchopulmonary aspergillosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125029052 | 12502905 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125029052 | 12502905 | Cholecystitis | |
| 125029052 | 12502905 | Drug interaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125029052 | 12502905 | 1 | 20160530 | 0 | ||
| 125029052 | 12502905 | 2 | 20160520 | 20160607 | 0 |